Akadeum Life Sciences Announces Two New Microbubble Kits at Advanced Therapies Week

he Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits use Akadeum’s BACS(TM) microbubbles to streamline cell therapy workflows.

Akadeum Life Sciences

Today, Akadeum Life Sciences, the market leader in buoyancy-based cell separation is announcing the release of a Human T Cell Selection, Activation, and Expansion Kit (GMP Grade), and a Human T Cell Depletion Kit (GMP Grade) at the Advanced Therapies Week on Jan 16. The kits add to Akadeum’s market-leading product portfolio in flotation-based technology, taking the company’s products one step further toward clinical trials.

2024 CAR T Cell Therapy Cost

In 2024, CAR T cell therapy can cost anywhere between $500,000 and $1 million per patient, predominantly because of the steep expense that existing manufacturing processes like magnets and columns require. The Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits will provide CDMOs, cell and gene therapy companies, and researchers the improved cell therapy workflows and cost-savings that existing methods of cell separation cannot provide.

Unlike microbubbles, magnetic beads and columns are limited in their selection capacity and can damage more sensitive cell types, potentially decreasing cell viability and risking population integrity.

The Human T Cell Selection, Activation, and Expansion kit

The Human T Cell Selection, Activation, and Expansion kit isolates and extracts highly pure populations of T cells and activates them for use in cell therapy workflows. By mixing the product into a sample, microbubbles positively select and bind to cells expressing CD3 and CD28, gently floating them to the surface of the mixture. The kit beats the efficiency of magnetic methods of selection, activation, and expansion by providing reduced cell exhaustion, increased numbers of activated T cell populations, and a highly scalable solution that fits into a variety of cell therapy workflows.

The Human T Cell Depletion Kit

The Human T Cell Depletion kit removes non-gene-edited cells from CAR T manufacturing cultures. The product positively selects unwanted T cells, leaving a highly pure and untouched sample of engineered cells ready for downstream formulation. The robust depletion kit allows for the increased recovery of gene-edited cells and maintains the improved health of the cell therapy product.

Casey Wegner, Vice President of R&D at Akadeum comments…

“Our innovative new GMP-compliant separation kits not only yield an unparalleled number of healthy cells, but provide a quicker and more cost-effective solution, expanding the horizon of possibility for researchers currently limited by time and cost constraints.”

“Cell and gene therapy companies utilizing magnetic beads and columns in their workflows will now be at a competitive disadvantage. Harnessing the power of gravity, Akadeum’s eco-friendly, gentle flotation technology rapidly produces healthy cells, empowering researchers to increase the accessibility and efficiency of CAR T cell therapy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy